Glitin M 2.5/500 F/C Tablet Tablet

Glitin M 2.5/500 F/C Tablet সম্পর্কে

Glitin M 2.5/500 F/C Tablet হলো Linagliptin + Metformin Hydrochloride-এর একটি ব্র্যান্ড, শক্তি ২.৫ mg + ৫০০ mg, ট্যাবলেট আকারে। Glitin M 2.5/500 F/C Tablet-এর সাথে Linagliptin + Metformin Hydrochloride-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। Glitin M 2.5/500 F/C Tablet প্রস্তুত করেছে Advanced Chemical Industries PLC। এই তথ্য শুধু জানার জন্য; ঔষধ সবসময় ডাক্তারের পরামর্শ অনুযায়ী খাবেন, মাত্রা বা ব্র্যান্ড নিয়ে প্রশ্ন থাকলে ফার্মাসিস্টকে জিজ্ঞেস করুন।

Linagliptin + Metformin Hydrochloride-এর ৩১টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Linatin M 2.5 mg + 500 mg Tablet-এর, প্রতি ইউনিট ৳ ৭.০০।

Glitin M 2.5/500 F/C Tablet কী?

Glitin M 2.5/500 F/C Tablet is an oral diabetes medicine for adults with type 2 diabetes, used alongside diet and exercise when treatment with both linagliptin and metformin is considered appropriate. Linagliptin works by slowing the breakdown of hormones that help release insulin when blood glucose is high and reduce glucagon. Metformin is a biguanide that helps control blood glucose levels. Together they support better glucose control. The doctor decides the dose and course for each person. The tablet is film-coated and contains 2.5 mg linagliptin with 500 mg metformin hydrochloride.

Glitin M 2.5/500 F/C Tablet-এর ব্যবহার

Glitin M 2.5/500 F/C Tablet is used in adults with type 2 diabetes as an add-on to diet and exercise, when a doctor judges that treatment with both linagliptin and metformin is suitable. It is not a replacement for healthy eating or activity. Whether it fits your situation depends on your medical history, kidney function and other medicines, so the doctor decides.

Glitin M 2.5/500 F/C Tablet কীভাবে ব্যবহার করবেন

Take Glitin M 2.5/500 F/C Tablet exactly as the doctor tells you. The doctor decides the dose and course, including any gradual change in dose to reduce stomach upset linked to metformin. Do not change the dose yourself. Ask the doctor or pharmacist about timing with meals and what to do if you miss a dose. Swallow the tablet as directed and keep it in a cool, dry place below 30°C, away from light, moisture and children.

Glitin M 2.5/500 F/C Tablet-এর পার্শ্বপ্রতিক্রিয়া

Common side effects include nasopharyngitis (cold-like symptoms) and diarrhoea. Low blood glucose (hypoglycemia) is more common when this medicine is used with sulfonylureas. Contact your doctor promptly if you suspect acute pancreatitis, which has been reported after marketing. Ask the doctor or pharmacist what warning signs to watch for and when to seek help, and report any side effect that worries you or does not settle.

সতর্কতা ও নিরাপত্তা

This combination is not for everyone. It is contraindicated in people with renal impairment, in acute or chronic metabolic acidosis such as diabetic ketoacidosis, and in anyone hypersensitive to linagliptin or metformin. Metformin is excreted by the kidneys, so the risk of accumulation and lactic acidosis rises as kidney function falls. There are no adequate well-controlled studies in pregnancy, so it should be used in pregnancy only if clearly needed, and caution is advised during breastfeeding. Tell your doctor about kidney problems, surgery, contrast imaging or other medicines first.

সাধারণ প্রশ্ন

What is Glitin M 2.5/500 F/C Tablet used for and what kind of medicine is it?

It is an oral combination medicine for adults with type 2 diabetes, containing linagliptin and metformin hydrochloride. It is used alongside diet and exercise when treatment with both ingredients is appropriate. The doctor decides whether it suits you.

What side effects should I watch for, and when should I call the doctor?

Common side effects include cold-like symptoms and diarrhoea, and low blood glucose is more likely when used with sulfonylureas. Call your doctor promptly if you suspect pancreatitis or feel very unwell, and ask the doctor or pharmacist which warning signs matter for you.

Is Glitin M 2.5/500 F/C Tablet safe in pregnancy or breastfeeding?

There are no adequate well-controlled studies of this combination in pregnant women, so it should be used in pregnancy only if clearly needed. Caution is advised during breastfeeding. Tell your doctor if you are pregnant, planning pregnancy or breastfeeding so they can advise you.

Who should not take Glitin M 2.5/500 F/C Tablet?

It is contraindicated in people with renal impairment, in acute or chronic metabolic acidosis such as diabetic ketoacidosis, and in anyone hypersensitive to linagliptin or metformin. Tell the doctor about kidney problems, surgery or contrast imaging before starting.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriate

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Linagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (β) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (α) cells in the circulation.

Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Linagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.

Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.

In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.

Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.

Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.

Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.

In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.

5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Cationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination.

P-glycoprotien/CYP3A4 inducer (i.e. rifampin)
: The efficacy of this medicine may be reduced when administered in combination.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Although Linagliptin undergoes minimal renal excretion, Metformin Hydrochloride is known to be substantially excreted by the kidney. The risk of Metformin Hydrochloride accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin Hydrochloride.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Most common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

In a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Linagliptin & Metformin. Temporarily discontinue Linagliptin & Metformin in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.

মাত্রাধিক্যতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

In the event of an overdose with this combination the usual supportive measures (i.e. remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely but Metformin Hydrochloride is dialyzable.

During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions.

Overdose of Metformin Hydrochloride has occurred in case of ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin Hydrochloride overdose cases.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

বিকল্প ব্র্যান্ড: Linagliptin + Metformin Hydrochloride

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

সব দেখুন ৩১ ব্র্যান্ড

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।